Number of courses of induction therapy independently predicts outcome after allogeneic transplantation for acute myeloid leukemia in first morphological remission.

[1]  H. Greinix,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease , 2015 .

[2]  B. Wood,et al.  Comparison of Minimal Residual Disease as Outcome Predictor for AML Patients in First Complete Remission Undergoing Myeloablative or Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation , 2013, Leukemia.

[3]  Daniel Wolff,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[4]  E. Estey,et al.  Rapid rate of peripheral blood blast clearance accurately predicts complete remission in acute myeloid leukemia , 2014, Leukemia.

[5]  E. Estey,et al.  Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. , 2013, Blood.

[6]  C. Hourigan,et al.  Minimal residual disease in acute myeloid leukaemia , 2013, Nature Reviews Clinical Oncology.

[7]  F. Appelbaum,et al.  Prognostic and therapeutic implications of minimal residual disease at the time of transplantation in acute leukemia , 2013, Bone Marrow Transplantation.

[8]  S. Lonial,et al.  Early clearance of peripheral blood blasts predicts response to induction chemotherapy in acute myeloid leukemia , 2012, Cancer.

[9]  R. Schlenk,et al.  The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach , 2012, Nature Reviews Clinical Oncology.

[10]  Todd A Alonzo,et al.  Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group. , 2012, Blood.

[11]  E. Copelan,et al.  Concise Review: The Role of Hematopoietic Stem Cell Transplantation in the Treatment of Acute Myeloid Leukemia , 2012, Stem cells.

[12]  F. Lo‐Coco,et al.  Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. , 2012, Blood.

[13]  A. Dominietto.  Minimal residual disease markers before and after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia , 2011, Current opinion in hematology.

[14]  E. Estey,et al.  Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  M. Tallman,et al.  Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis , 2010, Cancer.

[16]  R. Hills,et al.  Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. , 2010, Blood.

[17]  F. M. Stewart,et al.  Comparison of Matched Unrelated and Matched Related Donor Myeloablative Hematopoietic Cell Transplantation for Adults with Acute Myeloid Leukemia in First Remission , 2010, Leukemia.

[18]  Bob Löwenberg,et al.  Review Articles (434 articles) , 2008 .

[19]  C. Bloomfield,et al.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.

[20]  O. Casasnovas,et al.  Early clearance of peripheral blasts measured by flow cytometry during the first week of AML induction therapy as a new independent prognostic factor: a GOELAMS study , 2009, Leukemia.

[21]  H. Agut,et al.  Variability of gB and gH genes of human herpesvirus‐6 among clinical specimens , 2008, Journal of Medical Virology.

[22]  F. Mannelli,et al.  Peripheral blood blast clearance during induction therapy in acute myeloid leukemia. , 2008, Blood.

[23]  M. Tallman,et al.  Early peripheral blood blast clearance during induction chemotherapy for acute myeloid leukemia predicts superior relapse-free survival. , 2007, Blood.

[24]  M. Sorror,et al.  Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. , 2007, Blood.

[25]  F. Mannelli,et al.  Clearance of leukaemic blasts from peripheral blood during standard induction treatment predicts the bone marrow response in acute myeloid leukaemia: a pilot study , 2006, British journal of haematology.

[26]  M. Sorror,et al.  Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. , 2005, Blood.

[27]  K. Kawa,et al.  Impact of Cytogenetics on Outcome of Stem Cell Transplantation for Acute Myeloid Leukemia in First Remission: A Large-Scale Retrospective Analysis of Data from the Japan Society for Hematopoietic Cell Transplantation , 2004, International journal of hematology.

[28]  N. Lee,et al.  Parameters for predicting allogeneic PBSCT outcome of acute myeloid leukemia: cytogenetics at presentation versus disease status at transplantation , 2004, Annals of Hematology.

[29]  W. Hiddemann,et al.  Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial. , 2003, Blood.

[30]  R. Gray,et al.  A simple, robust, validated and highly predictive index for the determination of risk‐directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial , 1999, British journal of haematology.

[31]  A. Vekhoff,et al.  Prognostic factors of patients with acute myeloid leukemia (AML) allografted in first complete remission: an analysis of the EORTC-GIMEMA AML 8A trial , 1996 .

[32]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.

[33]  W. Woods,et al.  Allogeneic bone marrow transplantation for acute nonlymphocytic leukemia in first remission. , 1988, Blood.

[34]  W. Woods,et al.  Bone marrow transplantation for acute nonlymphocytic leukemia in first remission: analysis of prognostic factors. , 1985, Blood.